Golden
HUYA Bioscience International

HUYA Bioscience International

HUYA Bioscience International is a San Diego-based company founded by Mireille Gillings.

Founded in 2004, HUYA Bioscience International is a bio-science and biopharmaceutical company which works to identify and license pre-clinical and clinical-stage compounds coming out of China to leverage and extend research efforts and provide a bridge into international development. Through their model, HUYA tries to accelerate development while lowering business risk in introducing new compounds.

Compounds

HBI-8000

HBI-8000 is an orally taken, epigenetic drug, and a member of the benzamide class of histone deacetylase inhibitors which works to control how tightly DNA is wound around a histone protein. HBI-8000 looks to have immunomodulatory effects regulating antitumor activity and repression of genes associated with drug resistance. The product is currently undergoing a Phase II trial in the US to investigate efficacy and safety.

HBI-3000

HBI-3000 is an intravenous infusion administered multi-ion channel blocker treating atrial fibrillation. The compound is currently in Phase 1 testing.

HBI-3802

HBI-3802 is a small molecule with regenerative properties in cardiac muscle cells and possibly used after myocardial infarction, heart attacks, to strengthen and build the cardiac muscle. The compound stimulates cell differentiation into functional cardiomyocytes, replacing and remodeling dead myocardium with new functional tissue.

Funding

Venture Equity

HUYA Bioscience raised $5 million in April 2009. None of the investors were announced.

Debt Equity

In March of 2012, HUYA Bioscience raised $7.6 million in equity and debt financing. Investors were not announced. $3 million of the financing was through convertible promissory notes.

Debt Financing

HUYA Bioscience raised $48 million in debt financing in April 2015. Investors were not announced. The total amount raised was offered in convertible promissory notes.

Timeline

People

Name
Role
LinkedIn

Chen Yao, MD

Advisor



Christopher Kemmerer, PhD

Vice President, Chemistry, Manufacturing and Controls



Chun-Lin Chen, PhD, EMBA

Advisor



Clement Gingras

Chief Technology Officer and Chief Operating Officer Asia



Curtis Tyree, PhD

Senior Vice President, Strategic Planning



Gloria Lee, MD, PhD

Chief Medical Officer



Guozhong Rui, PhD

Advisor



Hiroshi Onogi, MD

Executive Vice President, Head of Clinical Development - Japan



Jin Li, MD

Advisor



Jonathan O'Connell

Chief Financial Officer



Jun Sun, PhD

Vice President, Business Development - China



Ken Nanami

Director, Clinical Operations



Kenneth D. Polin, Esq.

Chief Administrative Officer and General Counsel



Martin Doorbar

Global Head CMC and Manufacturing Operations



Masutoshi Toya

Clinical Project Management Director



Mireille Gillings, PhD, Hon DSc

CEO and Executive Chair



Qishan Wang, PhD

Director Shanghai Office, East China



Reid Bissonnette, PhD

Vice President, Pharmacology



Robert Goodenow, PhD

President



Rulun Zhou, MD, MS

Senior Director Beijing Office, North China



Shawn Shao-Hui Zhang, PhD

Advisor



Shun Lu, MD, PhD

Advisor



Suzanne Romano, PhD

Vice President, Product Evaluation & Early Stage Development



Xiaoping Ye, DPhil, EMBA

Advisor



Xinhui Luan, PhD

Advisor



Further reading

Title
Author
Link
Type
Date









Documentaries, videos and podcasts

Title
Date
Link





Companies

Company
CEO
Location
Products/Services









References